{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:51:35Z","timestamp":1774309895239,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0751-4","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:27:20Z","timestamp":1562250440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT"],"prefix":"10.1186","volume":"12","author":[{"name":"on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Piemontese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Arcese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar","family":"Gulbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","volume":"121","author":"P Di Bartolomeo","year":"2013","unstructured":"Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849\u201357.","journal-title":"Blood"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/leu.2014.180","volume":"29","author":"J Peccatori","year":"2015","unstructured":"Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396\u2013405.","journal-title":"Leukemia"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/sj.bmt.1703769","volume":"30","author":"SQ Ji","year":"2002","unstructured":"Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J, et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant. 2002;30:861\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"751_CR6","first-page":"10","volume":"19","author":"S Piemontese","year":"2017","unstructured":"Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;19:10\u201324.","journal-title":"J Hematol Oncol"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401\u201310.","journal-title":"Haematologica"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using posttransplantation cyclophosphamide results in outcomes equivalent of contemporaneous HLA-matched related or unrelated donor transplantation. J Clin Oncol. 2013;31:1310\u20136.","journal-title":"J Clin Oncol"},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.bbmt.2017.06.019","volume":"23","author":"M Slade","year":"2017","unstructured":"Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R. Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2017;23:1736\u201343.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang M-J, Bacigalupo A, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340.","journal-title":"Blood."},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/leu.2015.232","volume":"30","author":"O Ringd\u00e9n","year":"2016","unstructured":"Ringd\u00e9n O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447\u201355.","journal-title":"Leukemia"},{"issue":"8","key":"751_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"Dalila Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica. 2018 May 10. pii: haematol.2018.189258. doi: https:\/\/doi.org\/10.3324\/haematol.2018.189258 . [Epub ahead of print]","journal-title":"Haematologica"},{"key":"751_CR13","doi-asserted-by":"publisher","unstructured":"Zhang YY, Mo XD, Zhang XH, Xu LP, Wang Y, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplantation. Feb 2019. https:\/\/doi.org\/10.1038\/s41409-019-0456-x .","DOI":"10.1038\/s41409-019-0456-x"},{"issue":"1","key":"751_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41375-018-0170-5","volume":"33","author":"A Shimoni","year":"2019","unstructured":"Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2019;33(1):230\u20139.","journal-title":"Leukemia."},{"issue":"1","key":"751_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbmt.2017.10.002","volume":"24","author":"AM Raiola","year":"2018","unstructured":"Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transplant. 2018;24(1):119\u201326.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"751_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(2):257\u201365.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR17","doi-asserted-by":"publisher","unstructured":"Sun W, Mo XD, Zhang XH, Xu LP, Wang Y, et al. Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplant. 2018 Dec 5. https:\/\/doi.org\/10.1038\/s41409-018-0406-z [Epub ahead of print].","DOI":"10.1038\/s41409-018-0406-z"},{"issue":"7","key":"751_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/bmt.2016.62","volume":"51","author":"M Solh","year":"2016","unstructured":"Solh M, Zhang X, Connor K, Brown S, Solomon SR, et al. Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(7):949\u201354.","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"751_CR19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/ejh.12168","volume":"91","author":"CH Yan","year":"2013","unstructured":"Yan CH, Wang JZ, Liu DH, Xu LP, Chen H, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol. 2013;91(4):304\u201314.","journal-title":"Eur J Haematol."},{"key":"751_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on aGvHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant."},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant. 2003;9:215\u201333.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR22","unstructured":"MED \u2013 AB Forms Manual. A guide to the completion of the EBMT HSCT Med-AB forms. Last modified: 14\/05\/2018. http:\/\/www.ebmt.org\/sites\/default\/files\/2018-03\/MED-AB%20Forms%20Manual.pdf ."},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"issue":"4","key":"751_CR24","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"A. H. Goldstone","year":"2007","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALLTrial (MRC UKALLXII\/ECOG E2993). Blood. 2008;111:1827\u20131833.","journal-title":"Blood"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","volume":"20","author":"A Di Stasi","year":"2014","unstructured":"Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975\u201381.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","volume":"102","author":"SR McCurdy","year":"2017","unstructured":"McCurdy SR, Kasamon YL, Kanakry CG, Bola\u00f1os-Meade J, Tsai HL, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 Feb;102:391\u2013400.","journal-title":"Haematologica"},{"key":"751_CR27","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2015","unstructured":"Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2015;124:2735\u201343.","journal-title":"Blood."},{"key":"751_CR28","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the InternationalALLTrial (MRC UKALLXII\/ECOG E2993). Blood. 2008;111:1827\u201333.","journal-title":"Blood."},{"key":"751_CR29","doi-asserted-by":"publisher","unstructured":"Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission (Review) Cochrane Database Syst Rev. 2011;(10):CD008818. https:\/\/doi.org\/10.1002\/14651858.CD008818.pub2 .","DOI":"10.1002\/14651858.CD008818.pub2"},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532\u201343.","journal-title":"J Clin Oncol."},{"key":"751_CR31","doi-asserted-by":"publisher","unstructured":"Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017; 10: 113. Published online 2017 May 30. doi: https:\/\/doi.org\/10.1186\/s13045-017-0480-5","DOI":"10.1186\/s13045-017-0480-5"},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2017.10.023","volume":"24","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bola\u00f1os-Meade J, et al. Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24:343\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1432-2277.2011.01229.x","volume":"24","author":"Y Nannya","year":"2011","unstructured":"Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, Kurokawa M. The negative impact of female donor\/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transplant Int. 2011;24:469\u201376.","journal-title":"Transplant Int"},{"issue":"12","key":"751_CR34","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1158\/1078-0432.CCR-17-3622","volume":"24","author":"Fr\u00e9d\u00e9ric Baron","year":"2018","unstructured":"Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of donor type in patients with AML given allogeneic 2 hematopoietic cell transplantation after low-dose TBI based regimen. Clin Cancer Res. 2018. Published OnlineFirst on March 19, 2018; DOI: https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3622","journal-title":"Clinical Cancer Research"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","volume":"9","author":"MT Rubio","year":"2016","unstructured":"Rubio MT, Savani B, Labopin M, Piemontese S, Polge E, Ciceri F, et al. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol. 2016;9:25.","journal-title":"J Hematol Oncol"},{"key":"751_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","volume":"107","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138\u201350.","journal-title":"Int J Hematol"},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.bbmt.2016.01.013","volume":"22","author":"GJ Schiller","year":"2016","unstructured":"Schiller GJ, Tuttle P, Desai P. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-positive acute myelogenous leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biol Blood Marrow Transplant. 2016;22:982\u201390.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","volume":"48","author":"Guillermo Orti","year":"2017","unstructured":"Orti G, Barba P, Fox L, Salamero O, Bosch F, et Valcarcel D. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect. Exp Hematol. 2017;48:1-11. doi: https:\/\/doi.org\/10.1016\/j.exphem.2016.12.004 . Epub 2016 Dec 24.","journal-title":"Experimental Hematology"},{"key":"751_CR39","doi-asserted-by":"publisher","unstructured":"Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 May 14. https:\/\/doi.org\/10.1038\/s41409-019-0536-y [Epub ahead of print].","DOI":"10.1038\/s41409-019-0536-y"},{"key":"751_CR40","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","volume":"35","author":"A Bashey","year":"2017","unstructured":"Bashey A, Zhang M-J, SR MC. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017;35:3002\u20139.","journal-title":"J Clin Oncol"},{"key":"751_CR41","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cncr.31228","volume":"124","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, G\u00fclbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using post transplantation cyclophosphamide. Cancer. 2018;124:1428\u201337.","journal-title":"Cancer."},{"key":"751_CR42","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.bbmt.2014.08.023","volume":"20","author":"XD Mo","year":"2014","unstructured":"Mo XD, Kong J, Zhao T, Xu LP, Zhang XH, Liu DH, et al. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant. 2014;20:2023\u20138.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/bmt.2011.163","volume":"47","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Ikegame K, Kaida K, Taniguchi K, Kato R, Inoue T, et al. Incidence of extramedullary relapse after haploidentical SCT for advanced AML\/myelodysplastic syndrome. Bone Marrow Transplant. 2012;47:669\u201376.","journal-title":"Bone Marrow Transplant."},{"key":"751_CR44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/leu.2014.314","volume":"29","author":"L Crucitti","year":"2015","unstructured":"Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29:1143\u201352.","journal-title":"Leukemia."},{"key":"751_CR45","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.bbmt.2017.03.023","volume":"23","author":"N Shem-Tov","year":"2017","unstructured":"Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A, et al. Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2017;23:1087\u201394.","journal-title":"Biol Blood Marrow Transplant."},{"key":"751_CR46","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3324\/haematol.2010.025890","volume":"95","author":"WB Clark","year":"2010","unstructured":"Clark WB, Strickland SA, Barrett AJ, Savani BN. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodys-plastic syndrome. Haematologica. 2010;95:860\u20133.","journal-title":"Haematologica."},{"key":"751_CR47","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1080\/10428190600632857","volume":"47","author":"I Cunningham","year":"2006","unstructured":"Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma. 2006;47:1754\u201367.","journal-title":"Leuk Lymphoma."},{"key":"751_CR48","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology. J Clin Oncol. 2007;25:4938\u201345.","journal-title":"J Clin Oncol."},{"key":"751_CR49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"A Spyridonidis","year":"2012","unstructured":"Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26:1211\u20137.","journal-title":"Leukemia"},{"key":"751_CR50","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041\u201350.","journal-title":"Blood."},{"key":"751_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ejh.12647","volume":"96","author":"T De Freitas","year":"2015","unstructured":"De Freitas T, Marktel S, Piemontese S, Carrabba MG, Tresoldi C, Messina C, et al. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2015;96:629\u201336.","journal-title":"Eur J Haematol"},{"key":"751_CR52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/ejh.12832","volume":"98","author":"C Rautenberg","year":"2016","unstructured":"Rautenberg C, Nachtkamp K, Dienst A, Schmidt PV, Heyn C, Kondakci M, et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol. 2016;98:348\u201354.","journal-title":"Eur J Haematol"},{"key":"751_CR53","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259\u201371.","journal-title":"J Clin Oncol"},{"key":"751_CR54","first-page":"269","volume":"9","author":"M Mrsic","year":"1992","unstructured":"Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992;9:269\u201375.","journal-title":"Bone Marrow Transplant."},{"key":"751_CR55","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/bmt.2015.193","volume":"50","author":"G Andreola","year":"2015","unstructured":"Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of \u2a7e10\u2009years. Bone Marrow Transplant. 2015;50:1508\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"751_CR56","first-page":"273","volume":"130","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Labopin M, Nishihori T, Bazarbachi A, Finke J, et al. Outcomes of post-allograft relapsed acute myeloid leukemia after donor lymphocyte infusion or a second allogeneic hematopoietic cell transplant: a study of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood. 2017;130:273.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0751-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:40:56Z","timestamp":1721493656000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0751-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0751-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data for this retrospective multicenter analysis were provided and approved by the ALWP of the EBMT registry. Since 1990, patients have provided informed consent authorizing the use of their personal information for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}